The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Is a chemotherapy-free future in reach for selected patients with aggressive B-cell lymphomas?
In this video, Guilherme Perini, MD, Hospital Israelita Albert Einstein, São Paulo, Brazil, discusses the potential for implementing chemotherapy-free treatment for patients with aggressive B-cell lymphomas. Dr Perini notes that whilst chemotherapy-free treatment regimens currently remain out of reach, they tend to offer improved toxicity profiles, and encouraging outcomes have been observed with chemotherapy plus bispecific antibody combinations. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There’s always this question about going chemo-free in diffuse large B-cell lymphoma. I think this is really a reality in follicular lymphoma. Now we have very good results with chemo-free treatments. But in diffuse large cell lymphoma, I think what’s most important is disease control. Patients progressing and facing multiple lines of therapy, they eventually get worse disease and it’s even harder to treat them...
There’s always this question about going chemo-free in diffuse large B-cell lymphoma. I think this is really a reality in follicular lymphoma. Now we have very good results with chemo-free treatments. But in diffuse large cell lymphoma, I think what’s most important is disease control. Patients progressing and facing multiple lines of therapy, they eventually get worse disease and it’s even harder to treat them. So right now, I think what we can get the best results is the combination of chemotherapy with a bispecific antibody. So for now, I don’t think we’re 100% ready to go chemo-free. But we surely have a lot of new combinations on the horizon. So I really think it’s good. Patients like it. The toxicity profile of chemo-free regimens tends to be better than with chemotherapy. So I think it’s the future. But with the data that we have now, I am a little bit more cautious on going fully chemo-free.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
